Medical project manager using a laptop

Dimerix signs up first patient for ‘highly significant’ paediatric clinical trial

Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3
Free radicals

Publication highlights strengths of Memphasys’ antioxidant profiling system

Memphasys Ltd has seen a positive focus on its RoXsta antioxidant profiling system, through the publication…
A toilet in an abandoned spot

Immuron progresses development of traveller’s diarrhea drug Travelan

Immuron Ltd has presented a Clinical Study Report to the US Food and Drug Administration following…
AI image of a lung cross section

‘Billion dollar opportunity’: US DoD to fund ‘nuclear-free’ lung scanning pilot for 4DX

4D Medical's radioisotope-free lung scanning tech will form part of a US DoD paid pilot leading…
Monoclonal antibodies

Telix takes on ‘next-gen’ cancer drug candidates through $372m asset buy

Telix Pharmaceuticals Ltd has entered an asset purchase agreement with antibody engineering company ImaginAb, Inc
An owl cocks its head after reading the Mesoblast news

HotCopper users flock to make sense of darling Mesoblast’s ‘proposed financing’

If you’ve been paying attention, you know Mesoblast (ASX:MSB) is currently something of an Australian market darling.
Man handing cash to viewer

$8M deal sees Private Lantheus pick up 12.16% of Radiopharm Theranostics

Radiopharm has confirmed Lantheus, a similarly minded healthcare player, has acquired just over 12% of Radiopharm…
You did this. No, YOU did this.

Next Science stoush expands as ex-VP alleges fraud around breast implant IP

Next Science sued a former employee over breaching a non-compete clause; that employee counters with allegations…
Mosquito on human skin

Island enrols first subjects for Phase 2b clinical trial for dengue fever drug

Island Pharmaceuticals has enrolled its first four participants in a Phase 2b clinical trial to test…
Eye doctor concept

Biotech smallcap Opthea eyes 5% jump as key drug of interest validated in paper

Opthea has jumped to 77cps after having its diabetic eye drug of interest further validated as…